Literature DB >> 24718936

GPER mediates estrogen-induced signaling and proliferation in human breast epithelial cells and normal and malignant breast.

Eric R Prossnitz1, Helen J Hathaway1, Allison L Scaling1.   

Abstract

17β-Estradiol (estrogen), through receptor binding and activation, is required for mammary gland development. Estrogen stimulates epithelial proliferation in the mammary gland, promoting ductal elongation and morphogenesis. In addition to a developmental role, estrogen promotes proliferation in tumorigenic settings, particularly breast cancer. The proliferative effects of estrogen in the normal breast and breast tumors are attributed to estrogen receptor α. Although in vitro studies have demonstrated that the G protein-coupled estrogen receptor (GPER, previously called GPR30) can modulate proliferation in breast cancer cells both positively and negatively depending on cellular context, its role in proliferation in the intact normal or malignant breast remains unclear. Estrogen-induced GPER-dependent proliferation was assessed in the immortalized nontumorigenic human breast epithelial cell line, MCF10A, and an ex vivo organ culture model employing human breast tissue from reduction mammoplasty or tumor resections. Stimulation by estrogen and the GPER-selective agonist G-1 increased the mitotic index in MCF10A cells and proportion of cells in the cell cycle in human breast and breast cancer explants, suggesting increased proliferation. Inhibition of candidate signaling pathways that may link GPER activation to proliferation revealed a dependence on Src, epidermal growth factor receptor transactivation by heparin-bound EGF and subsequent ERK phosphorylation. Proliferation was not dependent on matrix metalloproteinase cleavage of membrane-bound pro-HB-EGF. The contribution of GPER to estrogen-induced proliferation in MCF10A cells and breast tissue was confirmed by the ability of GPER-selective antagonist G36 to abrogate estrogen- and G-1-induced proliferation, and the ability of siRNA knockdown of GPER to reduce estrogen- and G-1-induced proliferation in MCF10A cells. This is the first study to demonstrate GPER-dependent proliferation in primary normal and malignant human tissue, revealing a role for GPER in estrogen-induced breast physiology and pathology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24718936      PMCID: PMC4091989          DOI: 10.1007/s12672-014-0174-1

Source DB:  PubMed          Journal:  Horm Cancer        ISSN: 1868-8497            Impact factor:   3.869


  84 in total

1.  Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.

Authors:  M Bartucci; C Morelli; L Mauro; S Andò; E Surmacz
Journal:  Cancer Res       Date:  2001-09-15       Impact factor: 12.701

2.  Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.

Authors:  M J Ellis; A Coop; B Singh; L Mauriac; A Llombert-Cussac; F Jänicke; W R Miller; D B Evans; M Dugan; C Brady; E Quebe-Fehling; M Borgs
Journal:  J Clin Oncol       Date:  2001-09-15       Impact factor: 44.544

Review 3.  Src in cancer: deregulation and consequences for cell behaviour.

Authors:  Margaret C Frame
Journal:  Biochim Biophys Acta       Date:  2002-06-21

4.  The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells.

Authors:  Adele Vivacqua; Daniela Bonofiglio; Anna Grazia Recchia; Anna Maria Musti; Didier Picard; Sebastiano Andò; Marcello Maggiolini
Journal:  Mol Endocrinol       Date:  2005-10-20

Review 5.  Epidemiology of endocrine-related risk factors for breast cancer.

Authors:  Leslie Bernstein
Journal:  J Mammary Gland Biol Neoplasia       Date:  2002-01       Impact factor: 2.673

6.  In vivo effects of a GPR30 antagonist.

Authors:  Megan K Dennis; Ritwik Burai; Chinnasamy Ramesh; Whitney K Petrie; Sara N Alcon; Tapan K Nayak; Cristian G Bologa; Andrei Leitao; Eugen Brailoiu; Elena Deliu; Nae J Dun; Larry A Sklar; Helen J Hathaway; Jeffrey B Arterburn; Tudor I Oprea; Eric R Prossnitz
Journal:  Nat Chem Biol       Date:  2009-06       Impact factor: 15.040

7.  Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF.

Authors:  Deo Prakash Pandey; Rosamaria Lappano; Lidia Albanito; Antonio Madeo; Marcello Maggiolini; Didier Picard
Journal:  EMBO J       Date:  2009-01-15       Impact factor: 11.598

Review 8.  Amphiregulin: role in mammary gland development and breast cancer.

Authors:  Jean McBryan; Jillian Howlin; Silvia Napoletano; Finian Martin
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-04-09       Impact factor: 2.673

9.  The interactions between GPR30 and the major biomarkers in infiltrating ductal carcinoma of the breast in an Asian population.

Authors:  Wen-Hung Kuo; Li-Yun Chang; Daisy Li-Yu Liu; Hsiao-Lin Hwa; Jen-Jen Lin; Po-Huang Lee; Chiung-Nien Chen; Huang-Chun Lien; Ray-Hwang Yuan; Chia-Tung Shun; King-Jen Chang; Fon-Jou Hsieh
Journal:  Taiwan J Obstet Gynecol       Date:  2007-06       Impact factor: 1.705

10.  Inhibitory effects of estrogen receptor beta on specific hormone-responsive gene expression and association with disease outcome in primary breast cancer.

Authors:  Chin-Yo Lin; Anders Ström; Say Li Kong; Silke Kietz; Jane S Thomsen; Jason B S Tee; Vinsensius B Vega; Lance D Miller; Johanna Smeds; Jonas Bergh; Jan-Ake Gustafsson; Edison T Liu
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

View more
  37 in total

1.  Role of GPER in estrogen-dependent nitric oxide formation and vasodilation.

Authors:  Natalie C Fredette; Matthias R Meyer; Eric R Prossnitz
Journal:  J Steroid Biochem Mol Biol       Date:  2017-05-18       Impact factor: 4.292

2.  A Selective Ligand for Estrogen Receptor Proteins Discriminates Rapid and Genomic Signaling.

Authors:  Chetana M Revankar; Cristian G Bologa; Richard A Pepermans; Geetanjali Sharma; Whitney K Petrie; Sara N Alcon; Angela S Field; Chinnasamy Ramesh; Matthew A Parker; Nikolay P Savchuk; Larry A Sklar; Helen J Hathaway; Jeffrey B Arterburn; Tudor I Oprea; Eric R Prossnitz
Journal:  Cell Chem Biol       Date:  2019-11-06       Impact factor: 8.116

Review 3.  From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?

Authors:  Victoria Shang Wu; Noriko Kanaya; Chiao Lo; Joanne Mortimer; Shiuan Chen
Journal:  J Steroid Biochem Mol Biol       Date:  2015-05-18       Impact factor: 4.292

4.  Morphologic effects of estrogen stimulation on 3D MCF-7 microtissues.

Authors:  Marguerite M Vantangoli; Shelby Wilson; Samantha J Madnick; Susan M Huse; Kim Boekelheide
Journal:  Toxicol Lett       Date:  2016-02-24       Impact factor: 4.372

Review 5.  Twenty years of the G protein-coupled estrogen receptor GPER: Historical and personal perspectives.

Authors:  Matthias Barton; Edward J Filardo; Stephen J Lolait; Peter Thomas; Marcello Maggiolini; Eric R Prossnitz
Journal:  J Steroid Biochem Mol Biol       Date:  2017-03-25       Impact factor: 4.292

Review 6.  GPER modulators: Opportunity Nox on the heels of a class Akt.

Authors:  Eric R Prossnitz
Journal:  J Steroid Biochem Mol Biol       Date:  2017-03-08       Impact factor: 4.292

7.  Inhibition of growth hormone receptor by Somavert reduces expression of GPER and prevents growth stimulation of triple-negative breast cancer by 17β-estradiol.

Authors:  Rainer Girgert; Günter Emons; Carsten Gründker
Journal:  Oncol Lett       Date:  2018-04-18       Impact factor: 2.967

Review 8.  International Union of Basic and Clinical Pharmacology. XCVII. G Protein-Coupled Estrogen Receptor and Its Pharmacologic Modulators.

Authors:  Eric R Prossnitz; Jeffrey B Arterburn
Journal:  Pharmacol Rev       Date:  2015-07       Impact factor: 25.468

9.  Relevance of humanized three-dimensional tumor tissue models: a descriptive systematic literature review.

Authors:  D Contartese; Francesca Salamanna; F Veronesi; M Fini
Journal:  Cell Mol Life Sci       Date:  2020-04-13       Impact factor: 9.261

Review 10.  Emerging roles of GPER in diabetes and atherosclerosis.

Authors:  Matthias Barton; Eric R Prossnitz
Journal:  Trends Endocrinol Metab       Date:  2015-03-09       Impact factor: 12.015

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.